Terms: = Germ cell tumor AND MALAT1, PRO1073, 378938, Q9UHZ2 AND Prognosis
20 results:
1. Insights into the roles of non-coding RNAs and angiogenesis in glioblastoma: An overview of current research and future perspectives.
Song Z; Xue Z; Wang Y; Imran M; Assiri M; Fahad S
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130567. PubMed ID: 38242182
[TBL] [Abstract] [Full Text] [Related]
2. Identification and comparison of m6A modifications in glioblastoma non-coding RNAs with MeRIP-seq and Nanopore dRNA-seq.
Krusnauskas R; Stakaitis R; Steponaitis G; Almstrup K; Vaitkiene P
Epigenetics; 2023 Dec; 18(1):2163365. PubMed ID: 36597408
[TBL] [Abstract] [Full Text] [Related]
3. Integrated analysis to reveal potential therapeutic targets and prognostic biomarkers of skin cutaneous melanoma.
Zhou X; Rong R; Xiong S; Song W; Ji D; Xia X
Front Immunol; 2022; 13():914108. PubMed ID: 36032150
[TBL] [Abstract] [Full Text] [Related]
4. Long non-coding RNA panel as a molecular biomarker in glioma.
Ebrahimi AA; Ashoori H; Vahidian F; Mosleh IS; Kamian S
J Egypt Natl Canc Inst; 2021 Oct; 33(1):31. PubMed ID: 34693506
[TBL] [Abstract] [Full Text] [Related]
5. Long non-coding RNAs as a predictive markers of group 3 medulloblastomas.
Mutlu M; Tekin C; Ak Aksoy S; Taskapilioglu MO; Kaya S; Balcin RN; Ocak PE; Kocaeli H; Bekar A; Tolunay S; Tunca B
Neurol Res; 2022 Mar; 44(3):232-241. PubMed ID: 34533098
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
[TBL] [Abstract] [Full Text] [Related]
7. Coexistence of TERT C228T mutation and malat1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets.
Ak Aksoy S; Mutlu M; Tunca B; Kocaeli H; Taskapilioglu MO; Bekar A; Tekin C; Argadal OG; Civan MN; Kaya İS; Ocak PE; Tolunay S
Neurol Res; 2021 Nov; 43(11):916-925. PubMed ID: 34210246
[No Abstract] [Full Text] [Related]
8. METTL3 enhances the stability of malat1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.
Chang YZ; Chai RC; Pang B; Chang X; An SY; Zhang KN; Jiang T; Wang YZ
Cancer Lett; 2021 Jul; 511():36-46. PubMed ID: 33933553
[TBL] [Abstract] [Full Text] [Related]
9. Long Non-coding RNA malat1 Upregulates ZEB2 Expression to Promote Malignant Progression of Glioma by Attenuating miR-124.
Cheng H; Zhao H; Xiao X; Huang Q; Zeng W; Tian B; Ma T; Lu D; Jin Y; Li Y
Mol Neurobiol; 2021 Mar; 58(3):1006-1016. PubMed ID: 33078370
[TBL] [Abstract] [Full Text] [Related]
10. Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma.
Zhu J; Deng J; Zhang L; Zhao J; Zhou F; Liu N; Cai R; Wu J; Shu B; Qi S
BMC Cancer; 2020 Sep; 20(1):927. PubMed ID: 32993558
[TBL] [Abstract] [Full Text] [Related]
11. Long non-coding RNAs as epigenetic mediator and predictor of glioma progression, invasiveness, and prognosis.
Zhang Y; Xiao Y; Li GC; Gong FY; Zhang XN; Hou K
Semin Cancer Biol; 2022 Aug; 83():536-542. PubMed ID: 32920124
[TBL] [Abstract] [Full Text] [Related]
12. Long non-coding RNA malat1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles' heal?
Baspinar Y; Elmaci I; Ozpinar A; Altinoz MA
Gene; 2020 May; 739():144518. PubMed ID: 32119915
[TBL] [Abstract] [Full Text] [Related]
13. Long noncoding RNA malat1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas.
Argadal OG; Mutlu M; Ak Aksoy S; Kocaeli H; Tunca B; Civan MN; Egeli U; Cecener G; Bekar A; Taskapilioglu MO; Tekin C; Tezcan G; Tolunay S
Bosn J Basic Med Sci; 2020 Feb; 20(1):63-69. PubMed ID: 31479414
[TBL] [Abstract] [Full Text] [Related]
14. lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma: A systematic review and meta-analysis.
Zhou Q; Liu J; Quan J; Liu W; Tan H; Li W
Gene; 2018 Aug; 668():77-86. PubMed ID: 29777909
[TBL] [Abstract] [Full Text] [Related]
15. Long non-coding RNAs in melanoma.
Yu X; Zheng H; Tse G; Chan MT; Wu WK
Cell Prolif; 2018 Aug; 51(4):e12457. PubMed ID: 29582492
[TBL] [Abstract] [Full Text] [Related]
16. Targeted nanocomplex carrying siRNA against malat1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract] [Full Text] [Related]
17. malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma.
Fu Z; Luo W; Wang J; Peng T; Sun G; Shi J; Li Z; Zhang B
Biochem Biophys Res Commun; 2017 Oct; 492(3):480-486. PubMed ID: 28834690
[TBL] [Abstract] [Full Text] [Related]
18. malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract] [Full Text] [Related]
19. Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer cells Reveal New Insights into Molecular Determinants of cell Survival and tumor Progression.
Day TF; Mewani RR; Starr J; Li X; Chakravarty D; Ressom H; Zou X; Eidelman O; Pollard HB; Srivastava M; Kasid UN
Methods Mol Biol; 2017; 1513():83-100. PubMed ID: 27807832
[TBL] [Abstract] [Full Text] [Related]
20. Long noncoding RNA malat1 associates with the malignant status and poor prognosis in glioma.
Ma KX; Wang HJ; Li XR; Li T; Su G; Yang P; Wu JW
Tumour Biol; 2015 May; 36(5):3355-9. PubMed ID: 25613066
[TBL] [Abstract] [Full Text] [Related]
